Bone densitometry manufacturer Lunar issued a profit warning on Jan. 14, notifying investors that its financial results for the second fiscal quarter (end-December) will be below analysts’ expectations. The Madison, WI, firm said that U.S. sales
Bone densitometry manufacturer Lunar issued a profit warning on Jan. 14, notifying investors that its financial results for the second fiscal quarter (end-December) will be below analysts expectations. The Madison, WI, firm said that U.S. sales have been below the companys targets, and that the firms new Prodigy fan-beam densitometer has not had a chance to impact the companys results. Lunar introduced Prodigy at the RSNA conference last month (see story, page 3).
Lunar expects to report revenues of $23.4 million, an increase of 8% compared with $21.6 million in the same period a year ago. Net income swooned, however: Lunar expects to post a profit of $730,000, compared with net income of $2.7 million in the second quarter of 1998. The news prompted investors to sell Lunars stock, and shares of the company were trading at $9.13 on Jan. 15, a drop of 12%.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.